Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Ting Chou

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Oncogenesis|July 23, 2025
Targeting SLC7A5 in lung squamous cell carcinoma: implications for cancer metabolism shift and boron neutron capture therapy resistanceYen-Ju Lin, Yu-Cheng Wu, Yu-Jui Liu, et al.
Cancer Research|October 28, 2010
EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERFYu-Ting Chou, Hua-Heng Lin, Yung-Chang Lien, et al.
Autophagy|September 2, 2021
LC3A-mediated autophagy regulates lung cancer cell plasticityChia-Cheng Miao, Wen Hwang, Ling-Yi Chu, et al.
Cell|April 13, 2021
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granulesAsmin Tulpule, Juan Guan, Dana S Neel, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 8, 2024
Neutrophils Recruited by NKX2-1 Suppression via Activation of CXCLs/CXCR2 Axis Promote Lung Adenocarcinoma ProgressionAnita S La'ah, Ping-Hsing Tsai, Aliaksandr A Yarmishyn, et al.
Nature Communications|February 7, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Research Square|November 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
The Journal of Clinical Investigation|May 17, 2022
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancerShigeki Nanjo, Wei Wu, Niki Karachaliou, et al.
Biomaterials|December 24, 2025
Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerabilityMiao Huang, Yinong Chen, Chenyu Liang, et al.
Nature Communications|May 3, 2024
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancerFranziska Haderk, Yu-Ting Chou, Lauren Cech, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Oncogenesis|July 23, 2025
Targeting SLC7A5 in lung squamous cell carcinoma: implications for cancer metabolism shift and boron neutron capture therapy resistanceYen-Ju Lin, Yu-Cheng Wu, Yu-Jui Liu, et al.
Cancer Research|October 28, 2010
EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERFYu-Ting Chou, Hua-Heng Lin, Yung-Chang Lien, et al.
Autophagy|September 2, 2021
LC3A-mediated autophagy regulates lung cancer cell plasticityChia-Cheng Miao, Wen Hwang, Ling-Yi Chu, et al.
Cell|April 13, 2021
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granulesAsmin Tulpule, Juan Guan, Dana S Neel, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 8, 2024
Neutrophils Recruited by NKX2-1 Suppression via Activation of CXCLs/CXCR2 Axis Promote Lung Adenocarcinoma ProgressionAnita S La'ah, Ping-Hsing Tsai, Aliaksandr A Yarmishyn, et al.
Nature Communications|February 7, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Research Square|November 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
The Journal of Clinical Investigation|May 17, 2022
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancerShigeki Nanjo, Wei Wu, Niki Karachaliou, et al.
Biomaterials|December 24, 2025
Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerabilityMiao Huang, Yinong Chen, Chenyu Liang, et al.
Nature Communications|May 3, 2024
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancerFranziska Haderk, Yu-Ting Chou, Lauren Cech, et al.
Pageof 11